BIORA THERAPEUTICS INC (PROG)
US74319F1075 - Common Stock
BIOR Stock Starts Trading as Progenity’s Rebrand Takes Shape. What to Know.
Biora's product is supposed to enable biologics to be delivered directly to GI tracts. BIOR stock is a favorite of retail investors.
Progenity Announces Successful Transfer of Liquid Biopsy Technologies
Enumera Molecular Formed to Develop and Commercialize Next-Generation Solutions for Liquid Biopsy...
Progenity Appoints Paul Shabram to Lead Technical Operations of the Company’s Ingestible Drug/Device Platforms
Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms...
Progenity to Become Biora Therapeutics as it Completes Transformation
Upcoming Change Reflects the Company’s Focus on Oral Delivery of Biotherapeutics...
Progenity Announces Two Poster Presentations at Controlled Release Society 2022
SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning! It's time to start another busy day of trading with another breakdown of the biggest pre-market stock movers on Tuesday!
Progenity Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Accelerated Company Transformation Toward Oral Delivery of Biotherapeutics and Targeted Therapeutics Programs Progressed Company’s Targeted Therapeutics...
Interesting PROG Put And Call Options For May 20th
Progenity to Report Fourth Quarter and Full-Year 2021 Financial Results and Provide Corporate Update
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for...
Progenity Progresses its Drug Delivery System Clinical Device Performance Studies
Clinical Device Performance Study in Healthy Volunteers Demonstrated Accurate Localization and Delivery A Clinical Device Performance Study in Patients...
First Week of PROG April 22nd Options Trading
Interesting PROG Put And Call Options For April 1st
Progenity Announces Acceptance of Three Abstracts at Digestive Disease Week 2022
SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for...
Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22
Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting the hypotheses of targeted...
Progenity Shares Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology
Dr. Bram Verstockt presented key patient data establishing correlation between drug levels in colon and clinical outcomes...
10 Stocks to Buy That Could Make You a Millionaire in 2022
After this past year, it's going to be hard to find stocks to buy to make you a millionaire in 2022. Here are 10 that might do the trick.